Logo image of BOLT

BOLT BIOTHERAPEUTICS INC (BOLT) Stock Fundamental Analysis

USA - NASDAQ:BOLT - US0977022039 - Common Stock

4.48 USD
-0.3 (-6.28%)
Last: 11/7/2025, 1:38:47 PM
Fundamental Rating

3

Overall BOLT gets a fundamental rating of 3 out of 10. We evaluated BOLT against 534 industry peers in the Biotechnology industry. The financial health of BOLT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, BOLT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BOLT had negative earnings in the past year.
In the past year BOLT has reported a negative cash flow from operations.
BOLT had negative earnings in each of the past 5 years.
BOLT had a negative operating cash flow in each of the past 5 years.
BOLT Yearly Net Income VS EBIT VS OCF VS FCFBOLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

BOLT's Return On Assets of -67.17% is on the low side compared to the rest of the industry. BOLT is outperformed by 60.49% of its industry peers.
BOLT has a Return On Equity of -130.56%. This is in the lower half of the industry: BOLT underperforms 60.86% of its industry peers.
Industry RankSector Rank
ROA -67.17%
ROE -130.56%
ROIC N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
BOLT Yearly ROA, ROE, ROICBOLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

BOLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLT Yearly Profit, Operating, Gross MarginsBOLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BOLT has been increased compared to 1 year ago.
BOLT has more shares outstanding than it did 5 years ago.
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BOLT Yearly Shares OutstandingBOLT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
BOLT Yearly Total Debt VS Total AssetsBOLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -10.01, we must say that BOLT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.01, BOLT is not doing good in the industry: 72.47% of the companies in the same industry are doing better.
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.01
ROIC/WACCN/A
WACC8.81%
BOLT Yearly LT Debt VS Equity VS FCFBOLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.11 indicates that BOLT has no problem at all paying its short term obligations.
BOLT's Current ratio of 3.11 is on the low side compared to the rest of the industry. BOLT is outperformed by 63.67% of its industry peers.
BOLT has a Quick Ratio of 3.11. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
BOLT has a Quick ratio of 3.11. This is in the lower half of the industry: BOLT underperforms 60.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 3.11
BOLT Yearly Current Assets VS Current LiabilitesBOLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

BOLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.16%, which is quite impressive.
BOLT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.69%.
The Revenue has been growing by 103.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.52%
Revenue 1Y (TTM)-62.69%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%41.49%

3.2 Future

BOLT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.73% yearly.
Based on estimates for the next years, BOLT will show a quite strong growth in Revenue. The Revenue will grow by 14.46% on average per year.
EPS Next Y22.86%
EPS Next 2Y-9.06%
EPS Next 3Y5.83%
EPS Next 5Y5.73%
Revenue Next Year-47.76%
Revenue Next 2Y-34.56%
Revenue Next 3Y13.16%
Revenue Next 5Y14.46%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BOLT Yearly Revenue VS EstimatesBOLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5M 10M 15M
BOLT Yearly EPS VS EstimatesBOLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BOLT. In the last year negative earnings were reported.
Also next year BOLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLT Price Earnings VS Forward Price EarningsBOLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLT Per share dataBOLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20 -30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.06%
EPS Next 3Y5.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BOLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (11/7/2025, 1:38:47 PM)

4.48

-0.3 (-6.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10
Inst Owners44.61%
Inst Owner Change0%
Ins Owners0.63%
Ins Owner Change1.4%
Market Cap8.60M
Revenue(TTM)4.17M
Net Income(TTM)-50.71M
Analysts74.55
Price Target27.54 (514.73%)
Short Float %0.27%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.89%
Min EPS beat(2)21.57%
Max EPS beat(2)32.21%
EPS beat(4)3
Avg EPS beat(4)11.12%
Min EPS beat(4)-11.25%
Max EPS beat(4)32.21%
EPS beat(8)7
Avg EPS beat(8)14.59%
EPS beat(12)10
Avg EPS beat(12)12.17%
EPS beat(16)14
Avg EPS beat(16)11.76%
Revenue beat(2)2
Avg Revenue beat(2)85.92%
Min Revenue beat(2)56.1%
Max Revenue beat(2)115.75%
Revenue beat(4)2
Avg Revenue beat(4)15.11%
Min Revenue beat(4)-100%
Max Revenue beat(4)115.75%
Revenue beat(8)6
Avg Revenue beat(8)39.3%
Revenue beat(12)9
Avg Revenue beat(12)37.33%
Revenue beat(16)13
Avg Revenue beat(16)59.54%
PT rev (1m)-19.8%
PT rev (3m)-32.5%
EPS NQ rev (1m)9.04%
EPS NQ rev (3m)8.13%
EPS NY rev (1m)3.62%
EPS NY rev (3m)2.31%
Revenue NQ rev (1m)-9.37%
Revenue NQ rev (3m)-3.46%
Revenue NY rev (1m)-2.96%
Revenue NY rev (3m)25.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.06
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-25.86
EYN/A
EPS(NY)-36.16
Fwd EYN/A
FCF(TTM)-26.77
FCFYN/A
OCF(TTM)-26.75
OCFYN/A
SpS2.17
BVpS20.23
TBVpS20.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.17%
ROE -130.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 3.11
Altman-Z -10.01
F-Score1
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)172.25%
Cap/Sales(3y)12.39%
Cap/Sales(5y)328.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.52%
EPS Next Y22.86%
EPS Next 2Y-9.06%
EPS Next 3Y5.83%
EPS Next 5Y5.73%
Revenue 1Y (TTM)-62.69%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%41.49%
Revenue Next Year-47.76%
Revenue Next 2Y-34.56%
Revenue Next 3Y13.16%
Revenue Next 5Y14.46%
EBIT growth 1Y27.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.54%
OCF growth 3YN/A
OCF growth 5YN/A

BOLT BIOTHERAPEUTICS INC / BOLT FAQ

What is the ChartMill fundamental rating of BOLT BIOTHERAPEUTICS INC (BOLT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BOLT.


What is the valuation status for BOLT stock?

ChartMill assigns a valuation rating of 0 / 10 to BOLT BIOTHERAPEUTICS INC (BOLT). This can be considered as Overvalued.


What is the profitability of BOLT stock?

BOLT BIOTHERAPEUTICS INC (BOLT) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for BOLT stock?

The Earnings per Share (EPS) of BOLT BIOTHERAPEUTICS INC (BOLT) is expected to grow by 22.86% in the next year.